



## **Final Appraisal Recommendation**

Advice number: 0822 – April 2022

**Cariprazine (Reagila®) 1.5 mg, 3 mg, 4.5 mg, 6 mg hard capsules**

**Resubmission by Recordati Pharmaceuticals Ltd**

### **Recommendation of the All Wales Medicines Strategy Group**

**Cariprazine (Reagila®) is recommended as an option for restricted use within NHS Wales.**

**Cariprazine (Reagila®) should be restricted for use in the following subpopulation within its licensed indication for the treatment of schizophrenia in adults:**

- **for use as a second-line therapy in people with schizophrenia where predominantly negative symptoms have been identified.**

**Cariprazine (Reagila®) is not recommended for use within NHS Wales outside of this subpopulation.**

#### **Additional note(s):**

- AWMSG is of the opinion that cariprazine (Reagila®) may be appropriate for use within NHS Wales prescribed under specialist recommendation.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 5032), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

**Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:**

